SynthesisInternational journal of chronic obstructive pulmonary disease2018
The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review.
Synthesis in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Prevalence of depression in patients with sarcopenia and correlation between the two diseases: systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- From Airway Inflammation to Molecular Remodeling: Integrating YKL-40, MBL and Epigenetic Biomarkers in Asthma and COPD.Biomolecules · 2026Review
- CHI3L1 Expression in Neutrophils and Plasma of Multiple Sclerosis Patients: Implications for Pathogenesis and a Potential Biomarker.International journal of molecular sciences · 2026Article
- Nonlinear associations of the neutrophil-to-lymphocyte ratio and derived neutrophil-to-lymphocyte ratio with asthma-COPD overlap prevalence: a cross-sectional study.Frontiers in medicine · 2026Article
- Evaluating serum periostin and YKL-40 as biomarkers for airway remodeling and hyperresponsiveness in pediatric asthma.The World Allergy Organization journal · 2024Article
- The Role of Chitinase-3-like Protein-1 (YKL40) in the Therapy of Cancer and Other Chronic-Inflammation-Related Diseases.Pharmaceuticals (Basel, Switzerland) · 2024Review
- YKL-40 as a biomarker in various inflammatory diseases: A review.Biochemia medica · 2024Review
- Increased YKL-40 levels are linked with disease severity of initially diagnosed Graves' disease.The Libyan journal of medicine · 2023Article
- Serum MMP3 and IL1-RA levels may be useful biomarkers for detecting asthma and chronic obstructive pulmonary disease overlap in patients with asthma.The World Allergy Organization journal · 2023Article
- Serum YKL-40 Levels, Leukocyte Profiles, and Acute Exacerbations of Advanced COPD.Journal of clinical medicine · 2023Article
- Bronchial epithelial and airway smooth muscle cell interactions in health and disease.Heliyon · 2023Review
- Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study.Medicina (Kaunas, Lithuania) · 2023Article
- Effect of Vitamin D on YKL-40: Rat Hypercholesterolemia Model.Korean circulation journal · 2023Article
- Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study.Alzheimer's research & therapy · 2023Article
- YKL-40 as a possible marker of neutrophilic asthma.Frontiers in medicine · 2023Review
- Prediction value of neutrophil and eosinophil count at risk of COPD exacerbation.Annals of medicine · 2023Article
- Neutrophils and Asthma.Diagnostics (Basel, Switzerland) · 2022Review
- The Value of Serum YKL-40 and TNF-Cardiology research and practice · 2022Article
- Pharmacological Inhibition of Chitotriosidase (CHIT1) as a Novel Therapeutic Approach for Sarcoidosis.Journal of inflammation research · 2022Article
- Myokines: Novel therapeutic targets for diabetic nephropathy.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many studies have found that YKL-40 may play an important pathogenic role in COPD. However, the results of these studies were inconsistent. Therefore, we performed a systematic review and meta-analysis to investigate the role of YKL-40 in COPD. Methods: We performed a systematic literature search in many database and commercial internet search engines to identify studies involving the role of YKL-40 in patients with COPD. The standardized mean difference (SMD) and Fisher's Results: A total of 15 eligible articles including 16 case-control/cohort groups were included in the meta-analysis. The results indicated that the serum YKL-40 levels in patients with COPD were significantly higher than those in healthy controls (SMD =1.58, 95% CI =0.68-2.49, Conclusion: The current study suggests that YKL-40 may be implicated in bronchial inflammation and remodeling in COPD and may be considered as a useful biomarker for COPD diagnosis and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.